Targeted Therapy for Children with ALK-Driven Neuroblastoma

Investigational 3rd generation targeted drug to be studied as a treatment for pediatric patients with relapsed or refractory ALK-driven neuroblastoma

March 29, 2017 – NEW YORK, NY: Lorlatinib, an investigational drug candidate currently in late-stage clinical development for the treatment of lung cancer may also prove effective for the treatment of the pediatric cancer neuroblastoma. Solving Kids’ Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.

The phase I trial will be co-led by Dr. Yael Mossé at Children’s Hospital of Philadelphia (CHOP) and Dr. Araz Marachelian at Children’s Hospital of Los Angeles (CHLA), and will be conducted in 14 hospitals in the United States and Canada through the New Approaches to Neuroblastoma Therapy (NANT) consortium, as well as two European sites including Royal Marsden in London and Institut Curie in Paris. The study focuses on a subset of neuroblastoma patients with mutations in the anaplastic lymphoma kinase (ALK) gene. Abnormal ALK genes are found in 15 percent of high-risk neuroblastoma patients and portend a very poor prognosis.

The primary objective of this study is to identify a recommended Phase II dose and assess the anti-tumor activity as a result of administering this investigational drug candidate in pediatric patients with ALK-driven neuroblastoma. Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor that has been recently reported to show very compelling responses in lung cancer patients with ALK aberrations. The drug was specifically designed to inhibit tumor mutations that drive resistance. One important feature of this drug is that it penetrates the blood-brain barrier and may be effective in patients with relapsed neuroblastoma in the central nervous system.

“Lorlatinib has shown dramatic results in the lab against ALK+ neuroblastoma tumors in mice,” said Dr. Yael Mosse, the physician-scientist who discovered ALK mutations in neuroblastoma and led the preclinical investigations at the Children’s Hospital of Philadelphia. “If this trial proves successful, we expect the drug to quickly become part of frontline therapy in children with ALK-driven neuroblastoma – which is a tremendous accomplishment in cancer research, overall.”

The hope is that this trial will provide a foundation for future work, which could lead to approval by health authorities for this use. Only three drugs have ever been approved for pediatric cancers, and this would set a remarkable precedent for rapid introduction of a new drug.

“We are very pleased to be supporting a clinical trial site at the Royal Marsden Hospital, London, which enables children in the UK to access this exciting new agent close to home,” said Stephen Richards, Chief Executive Officer, Solving Kids’ Cancer Europe. “The trial, which is also accessible in continental Europe, marks a significant international collaboration and is something we are very proud of — effectively speeding up the advancement of better treatment for children with neuroblastoma.”

Childhood cancer is the leading cause of death by disease in the United States, and neuroblastoma is pediatric cancer that strikes mostly infants and young children. The aggressive cancer originates in the sympathetic nervous system and manifests as tumors in the neck, abdomen, and pelvis.

“We are excited to see such an innovative clinical trial come to fruition, and we are grateful to our partners who helped fund the gap so that we can continue in our joint mission to improve the overall survival rates for children diagnosed with neuroblastoma,” added Scott Kennedy, Executive Director, Solving Kids’ Cancer US. “This study represents an unprecedented collaboration between academic researchers, industry and charities to rapidly advance an exciting new agent, and provide access to the children who need it.”

###

COLLABORATIVE PARTNERS SUPPORTING THIS STUDY:
Solving Kids’ Cancer USA/EUR
The Band of Parents
The Ronan Thompson Foundation
The Children`s Neuroblastoma Cancer Foundation
Wade’s Army
The Catherine Elizabeth Blair Memorial Foundation
The Evan’s Victory Against Neuroblastoma Foundation
Also supported by community funds from families including Harrison Bate and Ellen’s Friends and Family

A group of logos for various organizations including band of parents bound by hope and solving kids ' cancer
A man and a little girl are sitting in front of a wooden wall.
By duda November 20, 2024
Ahana’s Story of Strength with High-Risk Neuroblastoma Every day, over 1,000 children worldwide are diagnosed with cancer,1 and for many families, that diagnosis means facing an uncertain future. At just 20 months old, Ahana was diagnosed with a rare and aggressive cancer that had already spread through her small body. Her family’s search for life-saving childhood cancer treatments led them from South Africa to Spain and possibly toward a clinical trial in New York. Ahana’s journey shows the importance of supporting organizations like Solving Kids’ Cancer, which works to find, fund, and advocate for advanced treatments that give hope to families fighting against tough-to-treat rare pediatric cancers.
A poster for 2024 year in review for solving kids ' cancer
November 11, 2024
Advancing Childhood Cancer Research: SKC’s 2024 Milestones
A group of children are holding a sign that says `` lace up for kids 2024 ''.
October 1, 2024
Lace Up for Kids: Your Impact on Childhood Cancer Research At Solving Kids’ Cancer, our mission has always been driven by hope — hope for better treatments, hope for breakthroughs, and most importantly, hope for every child fighting cancer. This year’s Lace Up for Kids campaign was nothing short of inspiring. Together, we’ve raised over $264,000 across the entire campaign, funding innovative childhood cancer research and providing more treatment options for children in need.  From coast to coast, nearly 4,000 participants have stepped up to lace up their gold shoelaces and make a difference. Whether it was through schools, sports teams, or community groups, the show of support has been overwhelming throughout the years. Over 7,823 donations have been made to accelerate new treatments, and the hashtag #CareWearShare has been used 13,864 times, spreading the message far and wide!
A girl is standing in front of a car in a parking lot.
September 2, 2024
Gold Laces for Childhood Cancer Awareness Month: Erin’s Story 
A group of children are standing in a circle with their shoes on the floor.
August 8, 2024
Smithtown Goes Gold for Childhood Cancer Awareness Month!
A poster for lace up for kids with a butterfly on it
August 6, 2024
Childhood Cancer Awareness Month: Lace Up for Kids 2024
A man standing on top of a mountain with the words osteosarcoma survivor to surgeon dr. kurt weiss ' story
August 1, 2024
Osteosarcoma Survivor to Surgeon: Dr. Kurt Weiss’ Story
Jacob 's journey : a childhood cancer survivor 's story
May 10, 2024
Jacob’s Journey: A Childhood Cancer Survivor’s Story Every battle has its heroes, and among the bravest are young children like Jacob Mozer, who faced stage 4 high-risk neuroblastoma when he was barely old enough to walk. Diagnosed at only 16 months old, Jacob’s early years were filled with constant medical appointments and intense treatments. Despite these challenges, today, Jacob is a shining example of the remarkable progress in pediatric oncology. He’s not merely surviving; he’s thriving as a pharmacy resident, driven to give back to the medical community that gave him a second chance at life. During National Cancer Survivors Month this June, we honor and celebrate fighters like Jacob who have battled cancer and emerged stronger. This month also serves to amplify the conversation about pediatric cancer survivorship and push for vital research that continues to save lives. Solving Kids’ Cancer (SKC) plays an essential role in this effort, supporting children like Jacob by funding crucial clinical trials that enhance survival rates and improve the quality of life for those fighting fatal childhood cancers.
A close up of a person holding a test tube in a laboratory.
May 2, 2024
Trailblazing Treatments for Pediatric Brain Tumors Picture a fortress built to guard precious treasure but accidentally also keeps out the very allies it needs in a time of crisis. This is the challenge faced by medical researchers when dealing with the brain’s natural defense — the blood-brain barrier — especially in children with brain tumors. At Columbia University Medical Center, Dr. Luca Szalontay is leading the charge to breach this fortress with groundbreaking approaches. Recently, Dr. Timothy Cripe from Solving Kids’ Cancer’s podcast, This Week in Pediatric Oncology (TWIPO) , interviewed Dr. Szalontay to delve deeper into these innovative treatments. This Brain Tumor Awareness Month, we’re shining a light on these important advances in treating children’s cancer. Understanding the Challenge Treating pediatric brain tumors like diffuse midline glioma (DMG) is especially tough because of the brain’s own protective shield, known as the blood-brain barrier. This barrier keeps out most chemotherapy drugs as well as large molecules, like antibodies, making it hard to treat the tumors effectively. Dr. Szalontay describes the dilemma: “Our field hasn’t been able to advance as quickly as it has with leukemias or other solid tumors because the drugs don’t penetrate the brain efficiently.” She adds on the nature of this blood-brain barrier, “It’s evolutionary, very important to protect us from different toxins and harmful agents, but this is a shield which protects the tumor as well.” Even when drugs work well in lab tests, they struggle to get to the tumor in strong enough doses without harming the body. Dr. Szalontay also points out that DMG tumors are found in very sensitive areas of the brain, making traditional surgery or radiation risky because they could damage vital brain functions. This makes finding safe and effective treatments for these tumors even more challenging. So, what’s being done to tackle these obstacles and help kids fight these tumors?
A group of stick figures are holding hands around a globe.
April 4, 2024
World Health Day: Pediatric Cancer’s Global Divide Imagine this: Two children, born at the same moment, oceans apart. In a country brimming with medical resources, one child quickly gets top-notch treatment for cancer. Meanwhile, across the globe, the other child faces a drastically different reality, with limited access to basic care. This isn’t just a thought experiment — it’s the harsh truth of pediatric cancer treatment worldwide. Observed every year on April 7, World Health Day shines a light on the mission to make healthcare accessible for all. This day is particularly significant in the context of pediatric cancer, where vast disparities in treatment availability highlight the global challenge of ensuring every child has the opportunity for health and healing. The Stark Contrast in Survival Rates: A Look at Pediatric Cancer Statistics Every day, more than 1,000 children are diagnosed with cancer, and the chances of survival vary greatly depending on where they live.1 Pediatric cancer survival rates serve as a clear indicator of the disparities between high-income countries (HICs) and low- and middle-income countries (LMICs). In wealthier nations such as the United States and Western Europe, the 5-year survival rate for children with cancer is over 80%, thanks to advanced healthcare systems and access to the latest treatments.2 But, here’s a troubling childhood cancer statistic: in LMICs where 80% of children with cancer live, fewer than 20% survive.1 This gap is due to several factors, including late diagnoses or, tragically, no diagnosis at all. Many children succumb to the disease without access to pain medication, and the burdens of travel and the high costs force most families to abandon care. These challenges are compounded by limited access to necessary treatments,3 as well as a lack of specialized equipment and trained healthcare professionals needed for effective pediatric cancer treatment. Addressing this divide requires a concerted global effort to improve early detection, make treatments more affordable, and enhance healthcare infrastructures, giving every child a fair chance to beat cancer. Navigating the Access Maze Access to cancer care shouldn’t be a treasure hunt. Yet, for many in LMICs, it feels like that — a relentless search for something seemingly out of reach. Here’s the reality revealed in childhood cancer statistics worldwide: many areas lack enough doctors who specialize in children’s cancer4 and the prices of cancer drugs can be sky-high.2 Even getting to a hospital can be an ordeal, with some families traveling hundreds of miles. And the financial strain? Devastating. The cost of care can quickly add up to more than a year’s income, forcing households into deep financial distress. In many LMICs, the lack of comprehensive insurance coverage means families are often left to pay for pediatric cancer treatment entirely out-of-pocket.5 Families often face the impossible choice between their child’s health and their financial survival. Solving Kids’ Cancer: Bridging the Gap Solving Kids’ Cancer (SKC) isn’t standing by; we’re on the front lines, actively working to make a difference in the global pediatric cancer landscape. Beyond funding research, advocating for policy changes, and fostering global partnerships, SKC is committed to educating and empowering the community to take action. We understand that while we might not have a global foothold to address every aspect of the pediatric cancer divide directly, there’s power in collective action. Through our efforts, we aim to catalyze advancements in pediatric cancer treatments and care that could dramatically change outcomes for children worldwide. • Research: We direct funds into cutting-edge studies, searching for breakthrough treatments that promise a brighter future for all kids, regardless of where they live. • Advocacy: We advocate for children’s needs by steering research funding towards unmet challenges and collaborating with experts to prioritize all children, including expanding trials to international sites to maximize access.2 • Global Partnerships: We don’t do it alone. By teaming up with researchers, hospitals, and other organizations across the globe, we’ve helped fund clinical trials that have extended to over 250 institutions across 15 countries worldwide . Uniting for a Cause Solving Kids’ Cancer extends its mission beyond research by fostering community and collaboration. Our signature event, Lace Up for Kids , held annually during September Childhood Cancer Awareness Month, is a powerful testament to this mission, drawing communities together to stand in solidarity against childhood cancer. Additionally, supporters can create their own fundraiser and have a platform to engage their local communities, sparking crucial conversations and garnering support for the cause. These initiatives highlight an important fact: While the challenge of pediatric cancer is significant, each of us has a part to play. By working together and supporting each other, we can fund the research needed to possibly change the direction of pediatric cancer treatment and care worldwide. World Health Day: A Chance for Every Child The fight against pediatric cancer is a stark reminder of the work ahead of us.6 It’s a battle that Solving Kids’ Cancer is dedicated to, but we need more than just our efforts — we need a global movement. This World Health Day, let’s rally for every child’s right to fight cancer on an even playing field. Donate today to help fund more innovative research and one day find a cure for childhood cancer — because every child, no matter where they are born, deserves a chance — a chance to fight, a chance to survive, and a chance to thrive.
More Posts